Redmile Group, LLC Cyma Bay Therapeutics, Inc. Transaction History

Redmile Group, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $9.85 Million - $15.5 Million	-1,719,247 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $148,736 - $324,352	44,800 Added 2.68%	1,719,247 $12.4 Million
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $1.52 Million - $4.57 Million	-1,076,169 Reduced 39.12%	1,674,447 $5.84 Million
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $78,686 - $127,156	-62,949 Reduced 2.24%	2,750,616 $4.07 Million
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $402,059 - $1.79 Million	-302,300 Reduced 9.7%	2,813,565 $5.52 Million

Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $115,200 - $162,225	-22,500 Reduced 0.72%	3,115,865 $16 Million
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $1.18 Million - $2.66 Million	194,600 Added 6.61%	3,138,365 $22.5 Million
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $41,616 - $68,442	-5,100 Reduced 0.17%	2,943,765 $39.1 Million
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $292,338 - $524,778	-44,700 Reduced 1.49%	2,948,865 $23.2 Million
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $389,504 - $519,816	35,800 Added 1.21%	2,993,565 $33.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $23,452 - $31,636	2,200 Added 0.07%	2,957,765 $39.7 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $8.58 Million - $14.5 Million	953,300 Added 47.61%	2,955,565 $0
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $2.72 Million - $3.31 Million	355,165 Added 21.56%	2,002,265 $18.4 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $9.8 Million - $13.6 Million	1,647,100	1,647,100 $13.3 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.